What Metotreksat Treats: Main Uses and Benefits

Metotreksat is an established medication prescribed to manage several medical conditions. Its primary therapeutic applications are focused on addressing certain autoimmune disorders and specific types of cancer.

Therapeutic Domains

In the treatment of autoimmune conditions, Metotreksat may help relieve inflammation and reduce the symptoms associated with rheumatoid arthritis in adults and certain polyarticular juvenile idiopathic arthritis. For psoriasis, it is used to manage severe, disabling cases that have not responded to other forms of therapy. The use of this agent is associated with a reduction in inflammation and may support overall symptom management across these domains.

In oncology, Metotreksat is indicated for the treatment of various neoplastic diseases. This includes certain types of choriocarcinoma and related trophoblastic tumors, as well as specific cases of leukemia and lymphoma.

Quick Facts

• Key Indications: Management of certain autoimmune conditions and specific cancers.
• Autoimmune Role: Used for severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and severe psoriasis.
• Oncology Role: Indicated in the treatment of specific leukemias, lymphomas, and trophoblastic tumors.
• Mechanism: Functions to slow the growth of cancer cells and manage inflammation in autoimmune diseases.

Who Can and Cannot Use Metotreksat?

Regulatory agencies strictly define eligibility for Methotrexate based on a patient’s health status and age, with specific conditions resulting in formal non-eligibility.

---

Populations for Whom Use is Contraindicated

Methotrexate is formally contraindicated (must not be used) for non-neoplastic indications in the following patient groups as documented in official labeling:

• Pregnant or Breastfeeding Women: Due to the risk of fetal harm and transfer into breast milk.
• Organ Dysfunction: Patients with severe renal impairment (typically creatinine clearance < 30 mL/min), severe hepatic impairment (e.g., cirrhosis), alcoholism, or chronic liver disease.
• Severe Blood/Immune Disorders: Patients with pre-existing severe blood dyscrasias (e.g., leukopenia, significant anemia) or overt immunodeficiency syndromes.
• Active Disease: Patients with active infectious disease (acute or chronic) or active peptic ulcer disease/ulcerative stomatitis.

---

Age-Related and Conditional Eligibility

• Adults: Eligible for major indications like severe Rheumatoid Arthritis and Psoriasis.
• Children/Adolescents: Eligible for Polyarticular Juvenile Idiopathic Arthritis (pJIA); however, efficacy is not established for other autoimmune uses like Psoriasis.
• Reproductive Restriction: Both male and female patients of reproductive potential are required to use effective contraception before, during, and for a specified period after therapy.
• Older Adults: Use requires caution and close monitoring due to potential age-related decrease in organ function.

Interactions with other medicines and products

Methotrexate's interaction profile is primarily defined by two regulatory concerns: substances that alter its exposure in the body and those that increase the risk of shared organ toxicity.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type	Interacting Substances/Categories	Official Regulatory Description
Reduced Clearance / Increased Exposure	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Probenecid, Penicillins, Proton Pump Inhibitors (PPIs)	These agents may lead to elevated and prolonged serum methotrexate levels by reducing renal tubular secretion, potentially resulting in toxicity.
Additive Toxicity (Hepatologic)	Alcohol (Ethanol), Retinoids, Azathioprine	Concurrent use increases the risk of additive hepatotoxicity (liver damage).
Additive Toxicity (Hematologic)	Antifolate drugs (e.g., Trimethoprim/Sulfamethoxazole), other myelosuppressive drugs (e.g., Leflunomide)	Increases the risk of severe additive haemotoxicity (bone marrow suppression) and is often formally contraindicated.

Contraindications and Constraints

Formal restrictions exist for certain combinations. Co-administration of live vaccines is prohibited due to the risk of severe infection. The regulatory labeling notes that highly protein-bound drugs (e.g., phenytoin) may increase the concentration of free methotrexate in the blood. Additionally, the use of vitamin preparations containing folic acid/folates may decrease the response to the medicine by counteracting its main effect. Patients with pre-existing renal impairment are documented to be at greater risk of severe adverse reactions from these pharmacokinetic interactions.

Methotrexate's action is fundamentally dual: it acts as a folate antagonist to restrict cell division and as a metabolic modulator to reduce inflammatory signaling.

---

Antagonism of the Folate Pathway and Cytostatic Action

The drug functions as a competitive inhibitor of the enzyme Dihydrofolate Reductase (DHFR), which is essential for activating the folate pathway. By blocking this primary biological target, Methotrexate starves rapidly dividing immune cells—like activated T-lymphocytes—of the necessary precursors to synthesize new DNA and RNA. This leads to a significant antiproliferative effect that limits the expansion of activated immune cell populations, thereby modulating systemic immune function.

---

Adenosine-Mediated Regulation of Inflammation

Methotrexate's active metabolite, Methotrexate Polyglutamates (MTX-PGs), accumulates within cells and blocks the enzyme ATIC in the purine synthesis pathway. This cascade causes the precursor AICAR to build up and be released as adenosine, a natural anti-inflammatory signaling molecule. Adenosine then binds to specific receptors on inflammatory cells, diminishing the production of pro-inflammatory cytokines (like TNF-alpha and IL-6) and inhibiting leukocyte activity, resulting in altered systemic inflammatory signaling.

---

⏳ Mechanism-Constrained Delayed Onset

The full immunomodulatory effect of the drug is biologically constrained because it relies on the slow, intracellular creation and accumulation of the active MTX-PGs required to engage the secondary ATIC target. This inherent time-dependency within the mechanism explains why the alteration in inflammatory pathways only fully materializes after several weeks of continuous engagement.

Metotreksat is administered through various official routes, including oral forms (tablets and solution) and parenteral forms (subcutaneous, intramuscular, and intravenous injection). For treating chronic inflammatory conditions like rheumatoid arthritis and psoriasis, the medicine must be administered strictly once weekly on a consistent day. This weekly schedule is a mandatory frequency pattern established to prevent the fatal toxicity associated with accidental daily dosing. The starting dose is typically low (e.g., 7.5 mg once weekly) and is subject to gradual adjustment to reach the lowest possible effective level for long-term maintenance.

The usage pattern for oncologic indications is distinctly different, relying on cyclic or intermittent administration schedules, often involving higher doses. For these intravenous protocols, the administration must occur under the supervision of physicians experienced in antimetabolite chemotherapy, and the total dose is frequently calculated based on Body Surface Area (mg/m^2). These high-dose regimens require mandatory supportive steps, including pre-treatment hydration, urine alkalization, and the essential use of leucovorin (folinic acid) rescue after the infusion to manage systemic drug clearance. Administration rules also specify that only preservative-free formulations must be used for intrathecal and high-dose IV routes, and that dosing requires mandated reduction for patients with renal impairment.

Research evidence / Overview of Studies for Metotreksat

Metotreksat was studied for decades across various long-term conditions and specific cancers. This overview describes the research landscape, including the types of studies that have been conducted and the specific health outcomes that were monitored. The research provides context but not individual predictions; findings describe group patterns, not personal outcomes.

---

Evidence for Use in Rheumatoid Arthritis (RA)

Research related to RA is extensive, drawing from many Randomized Controlled Trials (RCTs)—where patients are assigned to different treatment groups, sometimes including a placebo—and long-term observational studies that monitor patient groups over extended time intervals. This research has primarily examined adult populations with active RA.

Studies have monitored several types of outcomes related to systemic or functional imbalance. Researchers often use standardized clinical measures to track how symptoms change over time, such as criteria that look at the number of tender and swollen joints, and composite scores that indicate disease activity. Patient-reported outcomes describing perceived discomfort and the ability to perform daily functioning or activity level are also central to the findings. Additionally, long-term studies have tracked outcomes related to structural joint damage using radiographic evaluations (X-rays) over extended time intervals.

---

Evidence for Use in Severe Psoriasis

This block will describe the available clinical research supporting the use of the medicine for severe skin disease, noting the outcomes evaluated in trials (such as skin clearance scores) and the types of patient populations included.

The medicine was studied for adult populations with conditions involving periods of heightened symptoms, including those with chronic plaque psoriasis classified as moderate-to-severe. Studies in psoriasis monitored outcomes linked to inflammatory or irritative states in the skin. The main outcome used is the PASI score, which is a measurement used to track the percentage of skin clearance achieved during the study period. Findings describe patterns observed in the studies regarding the achievement of specific clearance thresholds over defined time intervals.

---

Extended Observation and Research Gaps

Research has explored whether the patterns observed in the studies of clinical response and functionality persist over time. Evidence quality varies across studies, particularly when comparing older, established data to the new, detailed research generated for newer therapies.

There is limited information for long-term outcomes in pediatric populations. Furthermore, comparative evidence is lacking in modern trials assessing the medicine as a monotherapy (used by itself) for RA and Psoriasis, as it is often studied as part of combination regimens.

How to Store and Dispose of Methotrexate

Methotrexate must be stored and handled according to strict regulatory guidelines due to its classification as a cytotoxic and hazardous drug.

---

Storage and Stability

• Temperature: Most unopened methotrexate tablets and vials must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Freezing must be avoided.
• Protection: The medicine must be protected from light and kept in its original container.
• In-Use Stability: Single-dose injection solutions must be discarded after one use. Multi-dose vials with preservative, when stored refrigerated (2 C to 8 C), must be used within 28 days of the first puncture.

Handling and Disposal

Methotrexate must be kept out of the reach of children.

Disposal must comply with federal, state, and local regulations for hazardous pharmaceutical waste. Used needles, syringes, and vials must be immediately placed into a dedicated, puncture-resistant sharps container and must not be placed in household garbage or flushed down the toilet.